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ABSTRACT 
Today’s medical devices are the lifesaving tool and these tools are very frequently used globally since long ago. With the increase in the number of 
medical devices and their uses, there is an increase in the number of adverse events related to such devices. That is why Materiovigilance is an 
important tool for the identification, collection, reporting, and analysis of any aversive catastrophe related to the use of medical devices and 
protection of a patient’s life by fending its reiteration. Post marketing surveillance of medical devices has been initiated in many countries, like the 
United States of America has started a program under the name Medical Device Reporting (MDR), France, Australia and the United Kingdom have 
also come up with their own programs. Apart from this India has also initiated the Materiovigilance program by Drug Controller General of India 
(DCGI) at the Indian Pharmacopoeia Commission (IPC) in Ghaziabad in 2015. In this article we have discussed about the risks associated with the 
use of different classes of medical devices and the need of Materiovigilance program. This article also discusses the adverse events associated with 
the medical devices, the reporting criteria of those adverse events and the different clinical events of the medical devices. 
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The term “vigilance” means close monitoring of the possible adverse 
effects [1-4]. Materiovigilance is the study of adverse events 
associated with the use of medical devices. It deals with the close 
monitoring of medical devices after post-marketing phase [1, 5]. The 
term “medical device” has been defined by the World Health 
Organization (WHO) as any instrument, apparatus, reagent for in 
vitro use, implant, device for tissue cutting or wound covering, 
highly sophisticated computerized medical equipment, software or 
other related or similar materials which are intended to be used for 
diagnosis, prevention, monitoring, treatment of disease [1, 4-8]. 
Although, the medical devices provide immense benefits to the 
patients, but the use of medical devices may also lead to some 
significant potential risks, sometimes life threatening [1, 7]. The 
risks that are associated with the use of medical devices include 
harmful effects, in particular, on the patients/users/healthcare 
professionals, interactions with other substances, certain 
contraindications and malfunctions. The risks can also include 
falsifications, technical defects and reduced efficacy [2, 6, 9-13]. This 
makes it essential to have a regulatory program to monitor these 
associated adverse effects. 
Materiovigilance deals with the identification, collection, reporting, 
estimating the undesirable occurrence and the possible management 
of adverse events associated with the use of medical devices, thus 
promoting patient health by preventing its recurrences [1, 5, 7]. The 
Materiovigilance program of India was launched on 6 July 2015 at 
the Indian Pharmaceutical Commission, Ghaziabad by DCGI [1, 2, 5] 
in order to track the medical devices and the associated adverse 
effects to ensure the safety, provide awareness, generate data, and 
promoting the patient safety [5, 7]. 
Scope and objective of materiovigilance 
The principle purposes of Materiovigilance are 
 To improve the protection of health safety of the patients, users 
and others by reducing the frequency of an incident [2, 3]. 
 To examine the proposed framework, and its implication, for the 
Indian medical device vigilance system to global harmonization, i.e., 
Global Harmonization Task Force (GHTF) [6]. 
 To bring solutions for the advancement of the use and 
productivity of the equipment [14]. 
 To create a nationwide system for patient safety monitoring. 
 To analyze the risk benefit ratio of medical devices used [15]. 
 To generate evidence-based data on the safety of medical devices. 
 To support Central Drugs Standard Control Organization (CDSCO) 
in the decision-making process on the use of medical devices. 
 To communicate safety information on the use of medical 
devices to various stakeholders to minimize the risk. 
 To emerge as a national center of excellence for materiovigilance 
activities. 
 To collaborate with other healthcare organizations and 
international agencies for the National Coordination Centre 
exchange of information and data management [4, 7]. 
 To sensitize manufacturers, importers, distributors of medical 
devices, including all healthcare stakeholders for better 
understanding of medical device standards for promotion of patient 
safety and strengthening of materiovigilance system. 
 To aware stakeholders about the need and significance of 
medical devices adverse events (MDAE) reporting [15, 16]. 
Methodology 
The publications, events related to medical devices and their 
adverse effects on Google, Google Scholar, PubMed, and Science 
Direct were searched with the search keywords such as “medical 
devices,” “adverse effects associated with medical devices,” 
“materiovigilance”, “case study related to medical devices” and in 
combination with each other with no particular time restriction in 
order to get a holistic and comprehensive view of the research done 
on this topic so far. 
Materiovigilance program of India (MvPI) 
In India, medical devices are classified as drugs and are regulated by 
drugs and cosmetic act and rules 1945 [6, 7, 17]. The MvPI is required to 
regulate the quality, efficacy, safety and availability of medical devices. 
The medical device rules, 2017 was brought to regulate the manufacture, 
import, sales, distribution of medical devices and came into force from 1 
January 2018 [18]. The Central Licensing Approving Authority in 
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October 2005, declared 10 devices to be considered as drugs. Medical 
devices which are classified as drugs include cardiac stents, drugs eluting 
stents, contraceptive implants, catheters, bone cement, i.e. cannula, 
intraocular lenses etc. [6, 15]. 
The MvPI aims at monitoring adverse events associated with the 
medical devices (medical device associated adverse events). In this 
program, the IPC functions as a national coordinating center and 
CDSCO as a regulator (fig. 1). The MvPI includes all private and 
public health care delivery system as well as the e-reporting system 
[2]. The MvPI was approved by Ministry of Health and Family 
Welfare on 10/2/15 and it was launched on 06/7/15 by DCGI at IPC, 
Ghaziabad, India [1, 5, 19]. 
Classification of medical devices 
Medical devices are classified by each regulatory authority in their 
own way. In general, the basis for medical devices are classified as 
on the basis of the risk associated with the medical device, 
manufacturers’ intended purpose for the device and the device’s 
indications for use [6, 16]. 
Classification of medical devices by the United States Food and 
drug administration (USFDA)  
USFDA has classified medical devices into three classes on the basis 
of level of control necessary to assure the safety and effectiveness of 
the device and on the basis of information about marketing 
requirements and has grouped them into 16 medical specialties 
(table 1) [6]. 
 
 
Fig. 1: Organizational structure of materiovigilance program of 
India [7]
 
Table 1: Classification of medical devices on the basis of USFDA 
Class Name of class Examples 
Class I General controls Elastic bandage and examination gloves 
Class II General controls and special controls Infusion pumps, surgical drapes, and ultrasound imaging systems 
Class III General controls and premarket approval Heart valves, and silicone gel-filled breast implants 
 
In addition to other things, the class to which your device is assigned 
determines the type of premarketing submission required for 
USFDA clearance to market. If the device is classified as Class I or II 
and not exempted, a 510k will be required for marketing. All devices 
classified as exempt face the limitations on exemptions. A Premarket 
Approval Application (PMA) will be required for class III devices 
unless the device is a pre-amendment device (on the market prior to 
the medical device amendments in 1976, or equivalent to such a 
device) and PMA's have not been called for. In such a condition, a 
510k will be the route to market [6, 20]. 
Classification of medical devices by the therapeutic goods 
administration (TGA) 
The TGA has classified medical devices into five classes on the basis 
of a set of four classification rules: invasive, non-invasive, active, and 
special type of devices, which are discussed in table 2 [6, 15]. 
 
Table 2: Classification of medical devices on the basis of TGA 
Class Risk Examples 
Class I Low risk Surgical microscopes and examination lights 
Class IIa Low to medium risk Electrical acupuncture and warming blankets 
Class IIb Medium to high risk Infant incubators and external defibrillators 
Class III High risk Heparin-coated catheters and biological heart valves 
Class IV Active implantable medical device (AIMD) Contraceptive intrauterine devices 
 
Classification of medical devices by the Medicines and 
Healthcare products Regulatory Agency (MHRA) 
Likewise, the MHRA has classified medical devices into different 
groups as [6, 21]: 
 General medical devices 
 AIMDs  
 In vitro diagnostic medical devices 
According to MHRA the general medical devices were then further 
classified into four classes as described in given table 3 [7, 21]. 
 
Table 3: MHRA classification of general medical devices 
Class of device Risk level Requirements Example 
Class I Low risk Premarket notification Dressings 
Class IIa Low–medium risk Certification by notified body X-ray film 
Class IIb Medium–high risk Certification by notified body Blood bags, contact lens care products 
Class III High risk Certification by notified body Bone cement, cardiac stents 
In India medical devices are not classified on the basis of risk in comparison to the regulated countries. Rather, the 10-device category of medical 
devices has been notified to be regulated as drugs [6]. 
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Table 4: Risk classification according to the New Zealand regulations 
AIMD Risk Implantable pacemaker 
Class III High Drug eluting cardiac stents 
Class IIb Medium to High Ventilators, orthopedic implants 
Class IIa Medium to Low Hypodermic needles, suction equipment 
Class I sterile Low Sterile dressings, non-medicated 
Class I measuring Low Volumetric urine bag 
Class I basic Low Reusable surgical instruments 
 
Risk classification according to the New Zealand regulations 
The New Zealand Regulations have five risk classes and two sub-
classes by following the principles of the GHTF. Based on the basis of 
the potential risk posed by the medical device when used as 
intended by the manufacturer, these are classified into different 
classes as shown in table 4 [22]. 
Adverse event reporting  
Adverse event reporting system helps in reporting the adverse 
events associated with the medical device. It is considered as an 
important tool through which all types of adverse events related to 
the medical device can be reported [3, 6, 16]. Reporting the adverse 
event will lead to the protection and improvement of health and 
safety of the patients or users. It gives us a way to prevent the future 
repetition of the adverse event to a particular device. All types of 
adverse events, whether serious, non-serious, adverse events which 
are pre-known or the incidents which are unknown [4, 5, 19, 23]. 
The guidance to the manufactures for reporting of adverse events 
associated with devices has been provided by GHTF. It gives the 
information on how to handle the information of the adverse event 
and to decide whether an event is reportable or not on the basis of 
information available [6, 16]. According to FDA’s regulation of 
medical device reporting, both the manufacturer as well as the 
importer is required to report the serious adverse events or the 
malfunctions and also it requires users to report the serious 
incidents associated with medical devices [6]. 
What to report 
Any type of adverse incident or event associated with the medical 
device can be reported. It can be serious, non-serious, pre-known, 
unknown. It can also be related to the inadequate description of the 
device and associated risks to the users. Inaccuracy in labelling as 
well as any malfunction can also be reported. Incidents can be of any 
type, it can be a frequently occurring event or a rare one, and both 
the types can be reported. Risks associated with the previous use to 
the patient can also be provided in the MDAE’s reporting form [1, 5, 
13, 23-26]. 
Where to report 
All the health care professionals, patients, users can report the 
MDAE’s to the Sree Chitra Tirunal Institute of Medical Science and 
Technology (SCTIMST) or National Coordinating Centre (NCC). The 
medical device adverse event reporting form can be filled and then 
it can be sent to SCTIMST, NCC or other stakeholders [5, 27]. The 
form can also be directly sent through email to mvpi@sctimst.ac.in 
[28]. 
How to report 
To report the medical device-associated adverse event, medical 
device adverse event reporting form can be downloaded from 
the official website of IPC www. ipc. gov. in [19, 29]. It is a two-
page form which is prepared by MvPI and contains all the 
information regarding the adverse event, the details of the 
patient, details of the device for which the adverse event is to be 
reported, the details of the reporter and the regulator 
(www.cdsco.nic.in/writereaddata/ MDadverseevent.pdf). The 
adverse event can also be reported by using the helpline number 
provided by NCC-PvPI which is 1800-180-3024. The reporter can 
call on this helpline number on weekdays from 9:00 am to 5:30 
pm [5, 23, 29-31]. 
Reporting criteria for adverse drug reaction found 
The reporting criteria include the following:  
 If an event has occurred, and the manufacturer becomes aware 
of the information. 
 If it is assessed that the manufacturer’s device is associated with 
the event based on the opinion from the available information. 
The FDA requires the manufacturer to report malfunctions and 
events occurring due to user errors as well as due to any defect in 
the medical device. The TGA also requires the sponsor or 
manufacturer to report malfunctions [6]. CDSCO [18, 19] must also 
report events that do not require to be reported under regulations 
so that trends or patterns of their occurrence can be monitored. 
Not-reportable incidents or events 
The regulated countries, along with India [6], defined not-reportable 
events similarly with few exceptions. The following events [6, 16, 32] 
are exempted from reporting in all countries:  
 If the deficiency of a device is found by the user before its use 
and no serious injury has occurred. 
 If the root cause of the adverse event is due to a patient’s pre-
existing condition. 
 If the shelf life or service life of the device was exceeded before 
its use by a patient. 
 If the deficiency had a negligible likelihood of causing death or 
serious injury and had been established and documented as 
acceptable after risk assessment. 
 If the side effects are expected and foreseeable from the 
manufacturer’s labelling, are clinically well known and are 
documented in the device master record, with an appropriate risk 
assessment. 
 If the adverse event was caused by abnormal use. 
Reporting time frame 
Although the report ability of the adverse event is uncertain, the 
GHTF [6, 16, 32] requires immediate reporting by the manufacturer 
of unanticipated death, serious injury and all other reportable events 
as soon as possible. If the adverse events are reported within the 
first 2 w based on an incomplete investigation, it may require a next 
follow-up report. The FDA [6] requires reporting of events not only 
by the manufacturer, whether domestic or foreign but also by the 
user facility and distributor. The manufacturer must submit four 
reports depending on the event reported: first, 30 d reports for 
death, serious injury, or malfunctions; second, 5 d reports for events 
requiring immediate remedial action (FDA form 3500A); third, 
baseline report (FDA form 3417) to provide basic data on the device, 
subject to MDR report (30 or 5 d); and finally, annual certification 
(FDA form 3381) [16, 32]. 
In Australia, although it is the manufacturer who must assess an 
incident, the sponsor is held accountable for forwarding information 
about events to the manufacturer and then for forwarding the 
results of any analysis to the TGA. Hence, the reporting time frame 
for reporting adverse events is as follows [6]: 
 Sponsor or manufacturer: they must report on form MDIR01 the 
following events:  
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• Death or serious deterioration in the state of health within 10 d. 
• Near adverse event or event that did not result in death or 
serious injury within 30 d. 
• Serious public health menace or aftercare and an event that 
requires expeditious remedial action within 48 h. 
• Complaints, malfunctions, and adverse events for class III and 
AIMD devices that have been reported for the year July 1, and 
October 1 following the entry of device in the Australian Register of 
Therapeutic Goods (ARTG) and for the subsequent 3 y. 
 Voluntary reporting by users of a suspected health hazard 
created by a medical device, on form UDIR01 [6, 33]. 
Under Incident Report Investigation Scheme of the TGA in United 
Kingdom, the manufacturer is required to report within the time 
frame the following reports upon becoming aware that an event has 
occurred and one of its devices has caused or contributed to the 
incident [6]: 
 Serious public threat within 2 d after the date of awareness. 
 Death or serious deterioration in the state of health within 10 
elapsed calendar days after the date of awareness. 
 Other incidents, immediately after assessing the link between 
the device and the event within 30 elapsed calendar days. 
 Manufacturer’s written acknowledgment of user reports from 
the MHRA to manufacturer within 3 working days of receiving user 
report. 
 Voluntary reports may be submitted at any time and maybe on 
the events other than death, serious injury, or malfunction as 
defined. 
The manufacturer’s incident report form should be used for 
beginning, follow-up, and final incident reports. If the report is made 
orally, it should be followed by a written report as soon as possible 
and a statement to the effect that the report is made by the 
manufacturer without prejudice and does not imply any admission 
of liability for the incident or its applicability. The manufacturer or 
authorized representative must submit an initial incident report to 
the MHRA for record and evaluation, followed by final reports. 
Types of reports 
According to FDA, depending on the reporting time frame, the types 
of reports that are to be submitted by a manufacturer are of five 
following types [6, 16, 32]: 
 30 d report: It involves the submission of reports within 30 d 
after the occurrence of the event. Information about death, serious 
injuries, any malfunction and adverse event reporting through 
complaint information is reported. 
 5 d report: in some cases, the report needs to be submitted 
within 5 d after the day you became aware of the need to submit 
such a report. This report is required to be submitted for certain 
serious, unexpected event which requires immediate remedial 
actions [6, 34]. 
 Baseline report: when an event for a device model or family is to 
be reported for the first time [6]. It can be of two types:  
• Model type: one report for each model, 
• Device family type: one report for all model in that family. 
 Supplemental report: it is the follow-up report, which is to be 
submitted within 1 mo after receipt of additional information. 
 Annual certification: this has to be submitted during the 12 mo 
period. The certifying officials assigned by the manufacturer should 
sign the certification statement for his identified organizational 
component/site to minimize the reporting errors [6, 16]. 
In the United Kingdom, the adverse event can be reported by 
submitting the reports in different forms such as an initial report, 
periodic summary report, trend report and final report. Whereas 
CDSCO in India has classified the reports as an initial report and final 
and/or trend report depending on time and date of report [6]. 
 
 
Fig. 2: Mandatory reporting requirements for manufacturers 
 
 
Fig. 3: Mandatory reporting requirements for importers [28] 
 
Vigilance exchange program or vigilance reporting 
National Competent Report System (NCRS) or vigilance exchange 
program provides guidance/procedures on how to handle the 
exchange of the two types of information [6, 35, 36]. 
 Highly sensitive/Confidential information  
 Public/Non-confidential information 
The necessity for vigilance exchange program depends on the 
seriousness, the unexpectedness of the incident, what type of 
population is more vulnerable, benefit/risk ratio, etc. The 
information exchanged includes the events for which the corrective 
measures are to be taken and can lead to serious risks in patients if 
remained unconsidered. NCRS forms have been posted by GHTF, 
which can be utilized to exchange the information directly to NCRS 
secretariat, which will help with appropriate global distribution. The 
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manufacturer’s report and the NCRS should be distributed within 14 
d after the event has reported by the manufacturer. 
Records 
Records are required to be maintained for each batch of a medical 
device. It gives information about the product, including its 
manufacturing, distribution and other relevant data. In order to aid 
MDR regulations, manufacturers are required to maintain certain 
written procedures to evaluate the information regarding report 
ability of an event, protocols that need to be followed during the 
investigation, for all reports that are submitted to FDA regarding 
MDR, etc. The records must contain all the history, reported 
incidents reported about each device as well as the actions taken 
should also be a part of that record. In case of an event, the records 
are required to be kept for 2 y or for a period equivalent to the 
suspected life of that device. The records must provide a detailed 
evaluation of each event report, user complaints, post-marketed 
clinical follow-up and so on. These should be maintained throughout 
the lifetime of the medical device [6, 37]. 
Enforcement actions 
The following enforcement actions have been incorporated by TGA, 
to ensure the supply of only safe, effective and quality medical 
devices in the market and for the maintenance of the vigilance 
program [6, 38]: 
 There are penalties for offenses 
 Cancellation of the medical device or, in some cases, suspension 
of a medical device from the ARTG 
 Recall of medical devices. 
For the regulation of medical devices, a number of enforcement 
actions have been described under the Consumer Protection Act 
1987, Medical Device Regulations 2002 and General Product Safety 
Regulations 2005 [6]. 
The CDSCO should incorporate the enforcement actions in case of a 
breach of regulations and should also include a recall system. 
Medical device regulations 2002 
Medical Device Regulations 2002 has been made on May 20, 2002, and 
came into force on June 13, 2002. Under section 2 of the European 
Communities Act 1972, the Secretary of State is a Minister is 
designated for the purpose of section 2, to take measures relating to 
medical devices, with the powers conferred by section 56 and of 
Finance Act 1973, i.e. in exercise with the consent of the Treasury, in 
exercise of the power under section 11 and 27 and in exercise of all the 
power after consultation in accordance with section 11 enabling him 
in that behalf, of Consumer Protection Act 1987, with the organization 
that appears to be representative of interest which are markedly 
affected by these Regulations and other persons which he considers 
appropriate and with the Health and Safety Commission [3]. 
Recall of devices 
While marketing a device, the manufacturer, distributor, or 
consumer might report complaints as some quality defects. If a 
complaint about a defect is not justified, then it is considered a 
failure of the quality system and immediate corrective action is 
undertaken by a product recall. 
The guidelines of MHRA [6, 39] and GHTF [6, 16] have termed recall 
a Field Safety Corrective Action (FSCA) to reduce the risk of harm to 
patients, operators, or others or to minimize the reoccurrence of the 
event. The FSCA would include the following actions:  
 Return of a medical device to the manufacturer or its 
representative (which is termed recall). 
 Device modification. 
 Device exchange. 
 Device destruction. 
 Advice is given by the manufacturer regarding the use of the 
device. 
The FSCA could reckon on different gait such as the return of a 
medical device to the supplier; device modification, exchange or 
destruction; retrofits by the purchaser of manufacturer’s 
modification or design change [6]; and any advice being given by the 
manufacturer on the use of the device. However, the manufacturer 
must distribute a Field Safety Notice (FSN) by appropriate means 
such as by confirmation of receipt. The FSN itself should include the 
following items:  
 A clear title like “Urgent Safety Notice” on the notice itself, on the 
envelope, if sent by mail, and as the subject line if sent by email or fax 
 The intended audience: a clear statement about the intended 
recipient of the notice 
 A concise description of the subject device (model, batch, or 
serial number) 
 The reasons for the FSCA are explained by the certain factual 
statement 
 A clear description of the hazards associated with the specific 
failure of the device and, where appropriate, the likelihood of 
occurrence, being mindful of the intended audience 
 The recommended action to be taken by the recipient of the FSN 
 Time frames by which the action should be taken by the 
manufacturer and user, where appropriate 
 Designated contact point for the recipient of the FSN to use to 
obtain further information. 
The notice must also include a request to inform customers or 
patients who received the product. The recalls have been classified 
on the basis of associated relative health hazard by both FDA and 
TGA as follows:  
 Class I: where severe adverse health consequences or death are 
likely. 
 Class II: where temporary or medically reversible health 
consequences are likely. 
 Class III: where use or exposure to the offending product will not 
likely cause adverse health consequences. 
Class I or class II recalls are considered to be urgent safety-related 
recalls, whereas class III recalls are considered to be routine 
nonsafety-related recalls. In addition, the TGA has classified recalls 
on the basis of the two-phase as premarketing and postmarketing 
phases [6, 40]. 
Premarketing phase 
 The manufacturer submits a device for assessment along with 
plans to monitor the performance of devices in use along with the 
response to any difficulty that may occur to the notified body. 
 The notified body conducts a conformity assessment for 
approval. In case of acceptance, ‘CE’ mark to the device will be 
certified to the manufacturer and the notified body also approves 
the system for monitoring the device’s performance and safety. 
 Medical Devices with ‘CE’ marking can be recognized mutually 
across all the European Union (EU) member states [2, 41]. 
Post marketing phase 
 All the adverse events are monitored by the manufacturer 
during the use of their device and necessary action is taken which is 
also known as FSCA for the reduction in the risk of death or serious 
fall in the state of health associated with the use of a medical device 
that is placed in the market. [MEDDEV 2 12-1 rev. 8 Vigilance]. 
 The adverse incident report related to the device is monitored 
by the competent authorities in each state (EU member) in their own 
country, along with the manufacturer’s investigation and responses. 
 Materiovigilance is designed to generate information for the 
identification of the problems related to the use of medical devices 
for the facilitation of the development of safety devices [2, 4, 41]. 
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Applications of materiovigilance 
 Diagnosis, monitoring, prevention, treatment, or mitigation of 
disease or compensation for an injury. 
 Improvement in design and efficiency of medical devices.  
 Reporting and investigation of the medical device-associated 
adverse events.  
 Implementation of corrective actions to prevent adverse events 
in future [1, 6, 27]. 
 Investigation, replacement, modification, or support of the 
anatomy or a physiological process. 
 Supporting or sustaining life. 
 Control of conception. 
 Disinfection of medical devices. 
 Providing information for medical purposes by means of in vitro 
examination (such as reagents, calibrators, sample collection kits, 
control materials and related instruments) of specimens derived 
from the human body [6]. 
Medical device tracking 
Medical device tracking has been included by the FDA as one of the 
post-marketing activities in order to track the device from the time 
of its manufacture up to the end-user [6]. Medical device tracking 
helps in locating the device in case of any defect or problems with 
the device [6, 28, 34, 42]. According to the FDA Act, there are certain 
devices which require tracking such as implantable devices, life-
sustaining or life-supporting devices, the failure of such devices will 
result in serious consequences [5, 6, 28]. The regulations 
implemented for the tracking of medical devices became effective on 
29 august 1993 and can be found in 21 CFR part 8216 [43]. 
The manufacturer is required to submit the information regarding 
the medical device whether the device has not or has been 
distributed to a patient within a period of 3-10 d [6]. The 
manufacturer needs to establish a written standard operating 
procedure for tracking the medical device which includes methods 
and other information regarding the tracking of the medical devices 
[28, 43]. The tracking is generally performed for any type of class II 
and class III devices. 
TGA has developed an Implantable Medical Device Tracking 
Subcommittee (IMDTS) for tracking of patients with implantable 
medical devices. However, in Europe, the Adverse Incident Tracking 
System (AITS) has to be followed. The adverse events can be 
categorized into one of the following investigational categories 
according to the revised MHRA directives [6]: 





In India, a lot number or a batch number is assigned to each device 
in order to make the tracking process easier. While assessing the 
link between the device and the adverse event, the manufacturer 
must take into account the following details:  
 Opinions from health care professionals  
 Previous similar events 
 Complaints trends  
 Other information held by the manufacturer. 
Clinical Investigation or case study about materiovigilance 
Mahajan et al., reported the impact of manufacturer advisories and 
FDA recalls of implantable cardioverter-defibrillator generators in 
paediatric and Congenital Heart Disease (CHD) patients from the 
year 2000-2005, it was found that about 25% of total patients had 
recalled devices and a significant proportion of patients underwent 
explantation. All these complications, though infrequent have 
important medical as well as psychological impacts and need to be 
monitored [44]. Beydon et al., studied adverse event reports 
associated with the medical devices used in anesthesia and intensive 
care in France. There was about 1004 adverse event reports in the 
year 1998 and about 11% cases were classified as serious and 2% 
deaths were also reported. There were several causes of failure of 
medical devices, the leading ones were user errors, quality control 
problems during the production of the devices and the design fault. 
32% of all reports in France was accounted for anesthesia in 1998. 
While 98% of the incidents were not fatal, but they required further 
examination as the problems with them were same as in the fatal 
incidents [45]. Laskey et al., performed an analysis of implantable 
cardiac device reliability from 2003-2007 in the United States. Data 
reports of devices such as Implantable Cardiac Defibrillators (ICDs) 
and Cardiac Resynchronization Therapy Defibrillator (CRT-D) 
implants, explants, and returned devices were analyzed. A 
statistically significant decrease in implantable cardiac device 
explantation was observed from year 2003-2007. However, the 
explantation rates of CRT-D devices remained significantly higher 
than ICD devices [46]. Golder et al., studied the failure or success of 
search strategies to identify adverse effects of medical devices and it 
was found that 51 were included on MEDLINE and 55 were included 
in EMBASE. Seven of EMBASE were found to be duplicates. Hence, 
creating a search filter for adverse effects of medical devices is 
reasonable and should be a research priority [47]. Dieffaga et al., 
performed a study on the materiovigilance and improvement of the 
maintenance of the biomedical equipment by the implementation of 
strategies for the use of equipment. This report was obtained from 
the case study of the hospital Gabriel Toure of Mali. There were 3 
persons able to select the parameter for the use of equipment. 11 
persons handle equipment of sterilization and 5 technicians handle 
radiographies. Only 8 agents move the equipment off after work. 18 
agents did not carry out maintenance of material after use. They 
recommend an internal alteration of the service of maintenance, the 
programming of regular supervision, the development and the 
application of the management tools of maintenance [14]. Brockton 
et al, studied about the adverse events of medical devices from 
Emergency Departments (ED). There were an estimated 454, 383 ED 
visits in a 12 mo period in the United States for an adverse event 
related to the medical device. Around 5350 cases contained two 
medical devices. The cases included many types of injury diagnoses. 
The most commonly injured site was the lower trunk (15%), 
followed by the finger (13%), and the eyeball (11%). About 13% of 
the total number involved patient hospitalization after ED 
evaluation. A planned collection of more comprehensive data will 
allow for appropriate public health interventions [48]. 
CONCLUSION 
In a few recent years, the use of medical devices is found to be very 
frequent by medical practitioners all over the world. Despite that, 
there are no substantial rules and regulations to protect the patients 
from aversive events related to the use of medical devices. 
Materiovigilance program is a good initiative by the different countries 
to ensure the safety of medical devices among the device users 
globally. This is requisite that emphatic implementation of this 
program will indemnity the safety of device users or patients. This 
program will be also significantly reducing the risk related to the use 
of medical devices by preventing the reduplication of aversive effects. 
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